In early 2026, key patents on semaglutide (key part of GLP drugs)-owned by Novo Nordisk and used in Ozempic- expired in India, opening the market to domestic manufacturers. Firms like Sun Pharma, Dr. Reddy’s Laboratories, and Zydus Lifesciences have begun trials and production of GLP-1 drugs (Ozempic, Mounjaro etc.). These patents are set to expire in the world soon as well.
Branded treatments from Novo Nordisk and Eli Lilly cost ~₹9,000–₹11,000/month, while Indian generics could drop to ₹1,500–₹4,000/month.